FDA approves Novavax COVID vaccine grown in moth cells — 100% efficacy claim based on just 14 placebo cases, raising serious safety concerns

FDA approves Novavax COVID vaccine grown in moth cells — 100% efficacy claim based on just 14 placebo cases, raising serious safety concerns

While the mainstream media touts Novavax’s Nuvaxovid as a “safer, more traditional” alternative to mRNA vaccines, the truth behind its FDA approval is far more unsettling. The agency green-lit this genetically engineered, insect-cell-derived vaccine based on shockingly weak evidence — just 14 moderate-to-severe COVID cases in the placebo group, with zero in the vaccinated group. This flimsy foundation allowed Novavax to claim 100% efficacy, a st…